Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)

Fig. 3

A Comparison of OS in patients with CBF-AML according GO treatment. B Comparison of CIR in patients with CBF-AML according GO treatment. C Comparison of OS in patients with inv(16) and t(8; 21) among the No-GO treatment cohort. D Comparison of CIR in patients with inv(16) and t(8; 21) among the No-GO treatment cohort. E Comparison of OS in patients with inv(16) and t(8; 21) among the GO treatment cohort. F Comparison of CIR in patients with inv(16) and t(8; 21) among the GO treatment cohort

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us